Brokerages Expect Supernus Pharmaceuticals Inc (SUPN) Will Post Quarterly Sales of $88.02 Million

Brokerages expect Supernus Pharmaceuticals Inc (NASDAQ:SUPN) to announce $88.02 million in sales for the current fiscal quarter, according to Zacks. Five analysts have issued estimates for Supernus Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $84.15 million and the highest estimate coming in at $92.17 million. Supernus Pharmaceuticals reported sales of $62.37 million in the same quarter last year, which indicates a positive year over year growth rate of 41.1%. The company is scheduled to announce its next quarterly earnings results on Tuesday, February 27th.

According to Zacks, analysts expect that Supernus Pharmaceuticals will report full-year sales of $88.02 million for the current fiscal year, with estimates ranging from $294.60 million to $305.98 million. For the next financial year, analysts anticipate that the company will post sales of $393.97 million per share, with estimates ranging from $385.13 million to $404.56 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Supernus Pharmaceuticals.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.27 by $0.02. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The company had revenue of $80.40 million during the quarter, compared to analyst estimates of $78.74 million. The business’s revenue was up 41.5% compared to the same quarter last year.

SUPN has been the subject of several recent analyst reports. Zacks Investment Research lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 12th. BidaskClub lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, January 26th. Piper Jaffray Companies set a $41.00 price objective on Supernus Pharmaceuticals and gave the stock a “hold” rating in a report on Sunday, October 29th. FBR & Co initiated coverage on Supernus Pharmaceuticals in a report on Thursday, October 19th. They set a “buy” rating and a $53.00 price objective for the company. Finally, B. Riley reissued a “buy” rating and set a $54.00 price objective on shares of Supernus Pharmaceuticals in a report on Thursday, January 18th. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Supernus Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $51.36.

In other Supernus Pharmaceuticals news, VP Victor Vaughn sold 55,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $40.11, for a total value of $2,206,050.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Gregory S. Patrick sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, January 11th. The stock was sold at an average price of $43.56, for a total value of $2,178,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 165,750 shares of company stock valued at $7,133,973. 6.70% of the stock is owned by insiders.

Institutional investors and hedge funds have recently modified their holdings of the business. Advisor Group Inc. lifted its position in Supernus Pharmaceuticals by 13.7% in the second quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock valued at $145,000 after purchasing an additional 410 shares during the last quarter. Public Employees Retirement Association of Colorado bought a new stake in Supernus Pharmaceuticals in the fourth quarter valued at approximately $188,000. Flinton Capital Management LLC lifted its position in Supernus Pharmaceuticals by 88.9% in the second quarter. Flinton Capital Management LLC now owns 4,760 shares of the specialty pharmaceutical company’s stock valued at $205,000 after purchasing an additional 2,240 shares during the last quarter. Balyasny Asset Management LLC bought a new stake in Supernus Pharmaceuticals in the second quarter valued at approximately $206,000. Finally, M&T Bank Corp bought a new stake in Supernus Pharmaceuticals in the second quarter valued at approximately $213,000. 98.71% of the stock is owned by institutional investors and hedge funds.

Supernus Pharmaceuticals (NASDAQ SUPN) opened at $38.40 on Tuesday. Supernus Pharmaceuticals has a twelve month low of $24.05 and a twelve month high of $50.04. The company has a market capitalization of $1,970.00, a PE ratio of 34.91 and a beta of 1.08.

ILLEGAL ACTIVITY NOTICE: This article was published by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was illegally stolen and republished in violation of international copyright and trademark laws. The legal version of this article can be read at https://www.americanbankingnews.com/2018/02/06/brokerages-expect-supernus-pharmaceuticals-inc-supn-will-post-quarterly-sales-of-88-02-million.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply